Skip to content

Glenmark’s US arm settles generic drug pricing case for $29.6 million

The company said Glenmark USA has denied all allegations and that the settlement “does not constitute any concession or admission of liability, wrongdoing, or illegality”.​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *